Eli Lilly and Company (NYSE:LLY) & MediciNova (NASDAQ:MNOV) Head to Head Comparison

Eli Lilly and Company (NYSE:LLY) and MediciNova (NASDAQ:MNOV) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares Eli Lilly and Company and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	31.90%	86.76%	22.03%
MediciNova	-1,168.70%	-26.51%	-24.39%

Earnings & Valuation

This table compares Eli Lilly and Company and MediciNova”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18 billion	20.68	$20.64 billion	$30.81	46.50
MediciNova	$410,000.00	168.07	-$12.00 million	($0.21)	-6.67

Eli Lilly and Company has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Eli Lilly and Company has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Eli Lilly and Company and MediciNova, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1	3	24	1	2.86
MediciNova	1	1	4	1	2.71

Eli Lilly and Company presently has a consensus target price of $1,416.64, indicating a potential downside of 1.11%. MediciNova has a consensus target price of $7.75, indicating a potential upside of 453.57%. Given MediciNova’s higher possible upside, analysts plainly believe MediciNova is more favorable than Eli Lilly and Company.

Summary

Eli Lilly and Company beats MediciNova on 9 of the 13 factors compared between the two stocks.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

About MediciNova

MediciNova, Inc. (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions. Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.